REFILE GlaxoSmithKline's breast cancer pill Tyverb gets Swiss approval |
|
|
|
Published
:
Wed, 23 May 2007 12:24 |
LONDON (Thomson Financial) - GlaxoSmithKline PLC said its breast cancer pill Tyverb has received marketing approval from the Swiss regulatory authority, Swissmedic.The world's second-biggest drug maker said it is on track to launch the drug across Europe in the second half of the year, pending further regulatory clearances. The company is still waiting for the green light from the European Medicines Agency.The drug was approved in the US last month, where it will be marketed as Tykerb.TFN.newsdesk@thomson.combsu/ssa/ab/dcaCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|